ADALAT

LOE ApproachingSM

nifedipine

NDAORALCAPSULE
Approved
Nov 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

CLINICAL PHARMACOLOGY Nifedipine is a calcium ion influx inhibitor (slow-channel blocker or calcium ion antagonist) which inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The contractile processes of vascular smooth muscle and cardiac muscle are…

Indications (1)

Clinical Trials (5)

NCT02047019Phase 3Withdrawn

Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil

Started Dec 2017
0
Hypertension
NCT03194633N/ACompleted

Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study

Started Jul 2017
871 enrolled
Hypertension
NCT02940548Phase 4Terminated

Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness

Started Dec 2016
99 enrolled
Hypertension
NCT02499822Phase 4Completed

REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial

Started Oct 2015
168 enrolled
HypertensionHigh Blood Pressure Variability
NCT02641821Phase 4Unknown

Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension

Started Oct 2015
700 enrolled
Hypertension